• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PRECOS awarded HTA license, expands PDX drug discovery models

PRECOS awarded HTA license, expands PDX drug discovery models

August 22, 2012
CenterWatch Staff

Preclinical Oncology Services (PRECOS), a pre-clinical research and development service provider focused on oncology, has been awarded a license to store and research human tissue samples by the Human Tissue Authority (HTA).

PRECOS will now be able to quickly and easily access patient tissue directly, allowing for greater access to samples for oncology model development by acquiring tissues for specific projects and cutting edge research. It also allows PRECOS and its customers greater scope for research opportunities across many cancer types. PRECOS utilizes methodology to retain the stromal elements of patient tissue which is important for sustaining heterogeneity and proper ligand-receptor interactions in cancer models which can then be used in a proprietary 3D tumour growth assay (TGA).

PRECOS has already established itself in the area of preclinical patient-derived tumor xenograft (PDX) modeling and possesses a collection that is widely believed to be more authentic, offering closer representation to the clinical setting. With increasing focus on subset specific panels of PDX for targeted therapies, genetic profiling and histological heterogeneity are paramount in recapitulating the clinical situation. Retention of the human stroma component in these models provides a more relevant heterogeneous system in which human tumor and stromal cells are in close co-operation within a unique microenvironment, thereby providing the right context to accurately and robustly evaluate the efficacy of a new therapeutic agent.

While the company has a primary focus in lung cancer PDX subsets, the acquisition of the HTA license will enable PRECOS to now invest in other cancer types, including breast and hematopoietic, to create panels of subtype specific PDX models with clinical information and original patient material for target identification, validation, through to lead optimization. The HTA license will also allow PRECOS to collect patient material in addition to tumor tissue, such as blood samples, normal tissue and other bodily fluids which can be used for biomarker assessment and more specific requirements such as assessment of circulating tumor cells. Direct access allows supply of samples to be tightly controlled and delivered with a specific protocol and timeframe and under the appropriate ethical review and consent. This means clients of PRECOS will now have a broader access to early-stage patient samples for specific studies as and when they are needed, offering greater flexibility and confidence.

Rajendra Kumari, COO of PRECOS, said, “Now we are able to procure, store and test a large number of samples sourced from Western societies, thereby enhancing the availability of Caucasian patient tissues and widening the geographical base and patient population of samples for our clients in U.K., Europe and U.S.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing